Business
Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares
Total gross proceeds from the offering to Cogent are approximately $115.0 million CAMBRIDGE, Mass., Dec. 4, 2020 /PRNewswire/ -- Cogent Biosciences, Inc.
About this update from Cogent Biosciences, Inc.
[{"type":"text","content":"Total gross proceeds from the offering to Cogent are approximately $115.0 million\n\n\nCAMBRIDGE, Mass., Dec. 4, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (\"Cogent\") (NASDAQ: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the closing of its upsized underwritten public offering of 11,794,872 shares of its common stock at a public offering price of $9.75 per share. This includes the exercise in full by the underwriters of their 30-day option to purchase up to 1,538,461 additional shares of common stock. The aggregate proceeds to Cogent from the offering, after deducting the underwriting discounts and commissions and before estimated offering expenses, were approximately $108.1 million.\n\n \n \n \n \n \n \n\n \nThe net proceeds from the offering will be used for the continued development, regulatory and commercial preparation of PLX9486 to treat patients living with systemic mastocytosis and gastrointestinal stromal tumors (GIST). \nJefferies and Piper Sandler & Co. acted as joint book-running managers for the offering. Wedbush PacGrow, LifeSci Capital and Ladenburg Thalmann also acted as co-managers for the offering.\nThe shares of common stock described above were offered by Cogent Biosciences, Inc. pursuant to a registration statement previously filed with the Securities and Exchange Commission (the \"SEC\") that became effective on May 1, 2019. A final prospectus supplement and accompanying prospectus were filed with the SEC and available for free on the SEC's website at http://www.sec.gov. Registration statements relating to the securities were filed with, and declared effective by, the Securities and Exchange Commission (the \"SEC\") and became effective on May 1, 2019. Copies of the registration statements can be accessed through the SEC's website at www.sec.gov. The offering was made only by means of a prospectus supplement and accompanying base prospectus. Copies of the final prospectus relating to the offering may be obtained from the SEC's website at www.sec.gov or by request to Jefferies LLC (Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022; telephone: 877-821-7388; email: [email protected]): or Piper Sandler & Co., Attention: Prospectus Department, 800 Nicolett M...